Labs / Assays & in vitro testing
Desentum
Espoo, Finland · desentum.fi
GMP
Desentum is a research-oriented clinical-stage biopharmaceutical company in Espoo, Finland. It develops allergen immunotherapy products for aeroallergens and food allergens, with lead programs in birch pollen, peanut, and cat allergy. The company works on recombinant hypoallergens designed for subcutaneous allergen immunotherapy.
They take quote requests by email.
What they offer
Allergen immunotherapy product development
Develops novel allergen immunotherapy products intended to change immune response from hypersensitivity to tolerance.
Recombinant hypoallergen design
Creates recombinant allergens with targeted modifications to reduce IgE cross-linking while retaining native conformation.
Controlled-release formulation development
Develops a formulation for controlled release of the active substance after injection.
Clinical development of investigational allergy treatments
Advances lead assets such as DM-101PX in clinical development for birch pollen allergy.
Preclinical development of allergy candidates
Develops hypoallergens for allergies including peanut, grass pollen, and cat allergy in preclinical development.
What they work on
- Modalities
- Antibody, Peptide
- Therapeutic areas
- allergies, birch pollen allergy, peanut allergy, cat allergy, grass pollen allergy
- Sites
- Espoo, Finland
- Founded
- 2011
Public records
- Ownership
- Desentum Oy · FI GLEIF
Similar labs. Bioneeds, Biofidus GmbH, EyeCRO, JPT Peptide Technologies
Found in a contract services directory. Listing built from desentum.fi. Work here? Claim this listing.